BioAge Labs, Inc (BIOA) Key Metrics
BIOA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $222.1M
- Enterprise value
- $44.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 21.5
- Price / book
- 1.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.08
BIOA key metrics, 2013–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBIOA valuation Price multiples at each fiscal year-end price.
Price / book+172.0%
1.7
2025 · hover or tap a bar for each year
20132025
Free cash flow yield+7.7 pts
−17.3%
2025 · hover or tap a bar for each year
20132025
BIOA returns How much profit the business earns on the capital it uses.
Return on equity+67.9 pts
−27.1%
2025 · hover or tap a bar for each year
20132025
Return on assets+12.3 pts
−24.7%
2025 · hover or tap a bar for each year
20132025
Free cash flow margin
−915.5%
2025 · hover or tap a bar for each year
20132025
Asset turnover
0.03
2025 · hover or tap a bar for each year
20132025
BIOA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.25
2025 · hover or tap a bar for each year
20132025
Earnings per share
−$2.24
2025 · hover or tap a bar for each year
20132025
Free cash flow per share
−$2.29
2025 · hover or tap a bar for each year
20132025
Book value per share−16.0%
$7.57
2025 · hover or tap a bar for each year
20132025
Shares outstanding+0.2%
35.9M
2025 · hover or tap a bar for each year
20132025
BIOA financial health Debt, liquidity and how easily interest is covered.
Debt / equity−24.1%
0.02
2025 · hover or tap a bar for each year
20132025
Net debt+$70.1M
−$275.5M
2025 · hover or tap a bar for each year
20132025
Current ratio+10.8%
14.24
2025 · hover or tap a bar for each year
20132025
Interest coverage
-133.1
2025 · hover or tap a bar for each year
20132025
Debt / assets−22.4%
0.02
2025 · hover or tap a bar for each year
20132025
BIOA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding
16 days
2025 · hover or tap a bar for each year
20132025
Days payables outstanding
4,001 days
2025 · hover or tap a bar for each year
20132025
Cash conversion cycle
-3,986 days
2025 · hover or tap a bar for each year
20132025
Capex / revenue
8.0%
2025 · hover or tap a bar for each year
20132025
BIOA valuation history
Fiscal year-endToday9-year median
BIOA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BIOA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BIOA cash returned to shareholders
DividendsBuybacksFree cash flow
BIOA price vs earnings per share
Share price at year-endEPS (right axis)
BIOA key metrics
2013–2025| 2025 | 2024 | 2023 | 2022 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $475.4M | $207.6M | — | — | — | — | — | — | — |
| Enterprise value | $199.9M | −$138.1M | — | — | — | — | — | — | — |
| Price / sales | 52.9 | — | — | — | — | — | — | — | — |
| Price / book | 1.7 | 0.6 | — | — | — | — | — | — | — |
| EV / sales | 22.2 | — | — | — | — | — | — | — | — |
| Earnings yield | −17.0% | −34.3% | — | — | — | — | — | — | — |
| Free cash flow yield | −17.3% | −25.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $13.23 | $5.79 | — | — | — | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.25 | $0.00 | $0.00 | $0.00 | $0.36 | $0.24 | $0.08 | $0.05 | $0.09 |
| Earnings per share | −$2.24 | −$1.98 | −$1.87 | −$1.16 | −$2.34 | −$0.66 | −$1.32 | −$1.65 | −$1.18 |
| Operating cash flow per share | −$2.27 | −$1.44 | −$1.09 | −$1.06 | −$0.71 | −$1.10 | −$1.14 | −$0.80 | −$0.98 |
| Free cash flow per share | −$2.29 | −$1.45 | −$1.10 | −$1.06 | −$0.71 | −$1.10 | −$1.14 | −$0.80 | −$1.43 |
| Cash per share | $7.82 | $9.88 | $0.63 | $0.81 | $0.11 | $0.47 | $0.25 | $1.81 | $2.97 |
| Book value per share | $7.57 | $9.01 | −$5.07 | −$3.29 | $0.52 | $1.42 | $1.64 | $2.04 | $2.31 |
| Tangible book value per share | $7.57 | $9.01 | −$5.07 | −$3.29 | $0.42 | $1.22 | $1.40 | $1.87 | $2.13 |
| Capex per share | $0.02 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.45 |
| Debt per share | $0.15 | $0.24 | $1.56 | $0.07 | $0.90 | $1.53 | $1.42 | $1.34 | $1.05 |
| Shares outstanding | 35.9M | 35.9M | 34.2M | 34.2M | 41.9M | 34.2M | 28.2M | 28.2M | 28.2M |
| Change in shares outstanding | +0.2% | +4.8% | +0.1% | −18.5% | +22.7% | +21.3% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −27.1% | −95.0% | — | — | −279.1% | −47.4% | −71.7% | −75.8% | −51.1% |
| Return on invested capital (ROIC) | — | — | — | — | −124.6% | −28.5% | −49.3% | −100.9% | −295.5% |
| Return on assets (ROA) | −24.7% | −37.0% | −235.0% | −81.1% | −85.0% | −14.8% | −25.2% | −34.8% | −29.1% |
| Return on tangible assets | −27.3% | −19.8% | −246.3% | −139.7% | −149.9% | −14.5% | −27.3% | −31.5% | −30.4% |
| Free cash flow margin | −915.5% | — | — | — | −199.4% | −454.7% | — | — | — |
| Financial health | |||||||||
| Total debt | $5.6M | $8.7M | $53.3M | $2.5M | $37.6M | $52.3M | $40.1M | $37.6M | $29.7M |
| Cash & short-term investments | $281.1M | $354.3M | $21.6M | $27.6M | $4.6M | $16.2M | $7.0M | $51.0M | $83.7M |
| Net debt | −$275.5M | −$345.6M | $31.6M | −$25.2M | $33.0M | $36.2M | $33.1M | −$13.4M | −$54.0M |
| Debt / equity | 0.02 | 0.03 | — | — | 1.72 | 1.08 | 0.86 | 0.65 | 0.46 |
| Debt / assets | 0.02 | 0.02 | 2.05 | 0.09 | 0.54 | 0.32 | 0.28 | 0.25 | 0.26 |
| Current ratio | 14.24 | 12.86 | 0.44 | 4.78 | 1.35 | 0.69 | 0.37 | 2.49 | 5.33 |
| Quick ratio | 14.24 | 12.86 | 0.44 | 4.78 | 0.92 | 0.59 | 0.31 | 2.41 | 5.20 |
| Interest coverage | -133.1 | -33.0 | -6.2 | -165.8 | — | — | — | — | -5.5 |
| Working capital | $266.7M | $329.3M | −$32.9M | $22.2M | $4.0M | −$13.9M | −$18.8M | $34.2M | $77.2M |
| Invested capital | −$3.5M | −$22.5M | −$141.8M | −$137.7M | $54.8M | $84.7M | $79.5M | $44.1M | $11.0M |
| Tangible asset value | $272.1M | $323.1M | −$173.4M | −$112.6M | $17.8M | $41.7M | $39.4M | $52.6M | $60.2M |
| Net current asset value | $264.0M | $322.0M | −$174.0M | −$113.0M | −$32.4M | −$81.4M | −$85.9M | −$37.8M | $45.9M |
| Graham net-net per share | $7.20 | $8.90 | −$5.20 | −$3.32 | −$0.88 | −$2.74 | −$3.13 | −$1.51 | $1.29 |
| Capital allocation | |||||||||
| Share buybacks (net) | — | — | — | — | $4.6M | $16.2M | $7.0M | $51.0M | $83.7M |
| Capex / revenue | 8.0% | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 479.8% |
| Capex / depreciation | 3.38 | 2.19 | 1.02 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 7.50 |
| Stock-based compensation / revenue | 130.0% | — | — | — | 34.7% | 43.3% | 220.6% | 450.4% | 252.6% |
| R&D / revenue | 822.3% | — | — | — | 36.6% | 87.0% | 934.0% | 982.2% | 622.1% |
| SG&A / revenue | 309.2% | — | — | — | 82.7% | 114.3% | 487.8% | 690.5% | 366.1% |
| Efficiency | |||||||||
| Days sales outstanding | 15.6 | — | — | — | 71.5 | 43.4 | 122.3 | 145.7 | 103.4 |
| Days of inventory on hand | — | — | — | — | 76.2 | 83.4 | 248.0 | 127.3 | 327.9 |
| Days payables outstanding | 4,001.3 | — | — | — | 99.5 | 291.9 | 1,174.7 | 30.6 | 4.0 |
| Cash conversion cycle (days) | -3,985.7 | — | — | — | 48.1 | -165.1 | -804.4 | 242.4 | 427.3 |
| Receivables turnover | 23.39 | — | — | — | 5.11 | 8.42 | 2.98 | 2.51 | 3.53 |
| Payables turnover | 0.09 | — | — | — | 3.67 | 1.25 | 0.31 | 11.93 | 91.16 |
| Inventory turnover | — | — | — | — | 4.79 | 4.38 | 1.47 | 2.87 | 1.11 |
| Asset turnover | 0.03 | 0.00 | 0.00 | 0.00 | 0.13 | 0.05 | 0.01 | 0.01 | 0.02 |
| Average receivables | $384,500 | $0 | — | — | $2.9M | $982,784 | $727,742 | $615,919 | $754,987 |
| Average payables | $2.3M | $1.9M | $2.1M | $4.2M | $6.1M | $10.9M | $8.4M | $506,481 | $29,497 |
| Average inventory | — | — | — | — | $4.7M | $3.1M | $1.8M | $2.1M | $2.4M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 5.8% | 4.2% | 4.9% | 3.3% | 4.3% |
Computed from BIOA's annual financial statements (latest annual report filed March 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BIOA valuation and financial ratios
BioAge Labs earned a return on equity of −27.1% in fiscal 2025. It ended the year with $5.6 million of debt and $281.1 million in cash and short-term investments, a net cash position of $275.5 million. The share count rose 27.5% from 28.2M to 35.9M over 8 years.
See the BIOA income statement, the BIOA chart for price history, or the BIOA stock overview for the latest quote and news.
BIOA key metrics FAQ
What is BioAge Labs's return on equity?
BioAge Labs's return on equity (ROE) was −27.1% in fiscal 2025: net income of -$80.6 million on average shareholders' equity of $297.6 million.
How much debt does BioAge Labs have?
BioAge Labs had total debt of $5.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is BioAge Labs's free cash flow yield?
BioAge Labs generated -$82.3 million of free cash flow in fiscal 2025, a free cash flow yield of −17.3% on its market value at year-end ($475.4 million).
What is BioAge Labs's current ratio?
BioAge Labs's current ratio was 14.24 at the end of fiscal 2025: current assets were 14.24 times current liabilities.